Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Apr. 01, 2023 | Apr. 25, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Period End Date | Apr. 01, 2023 | |
Document Transition Report | false | |
Document Quarterly Report | true | |
Entity File Number | 001-33264 | |
Entity Registrant Name | CARPARTS.COM, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 68-0623433 | |
Entity Address, Address Line One | 2050 W. 190th Street | |
Entity Address, Address Line Two | Suite 400 | |
Entity Address, City or Town | Torrance | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 90504 | |
City Area Code | 424 | |
Local Phone Number | 702-1455 | |
Title of 12(b) Security | Common Stock, $0.001 par value per share | |
Trading Symbol | PRTS | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Accelerated Filer | |
Smaller Reporting Company | false | |
Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 56,330,410 | |
Entity Central Index Key | 0001378950 | |
Current Fiscal Year End Date | --12-30 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Apr. 01, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 49,305 | $ 18,767 |
Accounts receivable, net | 9,745 | 6,406 |
Inventory, net | 112,364 | 136,026 |
Other current assets | 7,183 | 6,672 |
Total current assets | 178,597 | 167,871 |
Property and equipment, net | 24,423 | 24,290 |
Right-of-use - assets - operating leases, net | 22,850 | 23,951 |
Right-of-use - assets - finance leases, net | 18,401 | 19,750 |
Other non-current assets | 2,589 | 2,537 |
Total assets | 246,860 | 238,399 |
Current liabilities: | ||
Accounts payable | 55,221 | 57,616 |
Accrued expenses | 20,924 | 16,466 |
Right-of-use - obligation - operating, current | 4,640 | 4,571 |
Right-of-use - obligation - finance, current | 4,601 | 4,753 |
Other current liabilities | 6,071 | 4,622 |
Total current liabilities | 91,457 | 88,028 |
Right-of-use - obligation - operating, non-current | 20,306 | 21,412 |
Right-of-use - obligation - finance, non-current | 14,826 | 15,916 |
Other non-current liabilities | 3,202 | 2,971 |
Total liabilities | 129,791 | 128,327 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Common stock, $0.001 par value; 100,000 shares authorized; 54,693 and 52,960 shares issued and outstanding as of December 31, 2022 and January 1, 2022 (of which 2,565 are treasury stock) | 59 | 57 |
Treasury stock | (7,625) | (7,625) |
Additional paid-in capital | 303,185 | 297,265 |
Accumulated other comprehensive income | 1,150 | 1,126 |
Accumulated deficit | (179,700) | (180,751) |
Total stockholders' equity | 117,069 | 110,072 |
Total liabilities and stockholders' equity | $ 246,860 | $ 238,399 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands | Apr. 01, 2023 | Jan. 02, 2022 |
CONSOLIDATED BALANCE SHEETS | ||
Common stock, par value (in USD per share) | $ 0.001 | |
Common stock, shares authorized (in shares) | 100,000 | |
Common stock, shares issued (in shares) | 56,203 | 54,693 |
Common stock, shares outstanding (in shares) | 54,558 | 52,960 |
Treasury stock (in shares) | 2,565 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | ||
Apr. 01, 2023 | Apr. 02, 2022 | ||
Income Statement [Abstract] | |||
Net sales | $ 175,492 | $ 166,053 | |
Cost of sales (1) | [1] | 112,941 | 104,891 |
Gross profit | 62,551 | 61,162 | |
Operating expenses | |||
Operating expense | 61,915 | 58,771 | |
Income (loss) from operations | 636 | 2,391 | |
Other income (expense): | |||
Other, net | 914 | 56 | |
Interest expense | (358) | (292) | |
Total other expense, net | 556 | (236) | |
Loss before income taxes | 1,192 | 2,155 | |
Income tax provision | 141 | 52 | |
Net loss | 1,051 | 2,103 | |
Other comprehensive gain (loss): | |||
Foreign currency translation adjustments | 20 | ||
Unrealized (loss) gain on deferred compensation trust assets | 24 | (34) | |
Total other comprehensive gain (loss) | 24 | (14) | |
Comprehensive loss | $ 1,075 | $ 2,089 | |
Net Loss Per Share | |||
Basic net loss per share | $ 0.02 | $ 0.04 | |
Diluted net loss per share | $ 0.02 | $ 0.04 | |
Weighted-average common shares outstanding: | |||
Shares used in computation of basic net loss per share | 55,047 | 53,251 | |
Shares used in computation of diluted net loss per share | 58,037 | 57,172 | |
[1] Excludes depreciation and amortization expense which is included in operating expense. |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands | Common Stock | Additional Paid-in- Capital | Treasury Stock | Accumulated Other Comprehensive (Loss) Income | Accumulated Deficit | Total |
Beginning balance at Jan. 01, 2022 | $ 56 | $ 282,663 | $ (7,625) | $ 274 | $ (179,800) | $ 95,568 |
Beginning balance (in shares) at Jan. 01, 2022 | 52,960 | |||||
Increase (Decrease) in Stockholders' Equity | ||||||
Net income (loss) | 2,103 | 2,103 | ||||
Issuance of common stock, net of underwriters' offering expenses and commissions | 792 | 792 | ||||
Issuance of shares in connection with stock option exercise (in shares) | 533 | |||||
Issuance of shares in connection with restricted stock units vesting | $ 1 | (1) | ||||
Issuance of shares in connection with restricted stock units vesting (in shares) | 519 | |||||
Issuance of stock awards | 81 | 81 | ||||
Issuance of stock awards (in shares) | 10 | |||||
Issuance of shares in connection with BOD Fees | 6 | 6 | ||||
Issuance of shares in connection with ESPP | 431 | 431 | ||||
Issuance of shares in connection with ESPP (in shares) | 45 | |||||
Officers and directors stock purchase plan | 23 | 23 | ||||
Officers and directors stock purchase plan (in shares) | 3 | |||||
Share-based compensation | 4,225 | 4,225 | ||||
Unrealized gain (loss) on deferred compensation trust assets | (34) | (34) | ||||
Effect of changes in foreign currencies | 20 | 20 | ||||
Ending balance at Apr. 02, 2022 | $ 57 | 288,220 | (7,625) | 260 | (177,697) | 103,215 |
Ending balance (in shares) at Apr. 02, 2022 | 54,070 | |||||
Beginning balance at Dec. 31, 2022 | $ 57 | 297,265 | (7,625) | 1,126 | (180,751) | 110,072 |
Beginning balance (in shares) at Dec. 31, 2022 | 54,693 | |||||
Increase (Decrease) in Stockholders' Equity | ||||||
Net income (loss) | 1,051 | 1,051 | ||||
Issuance of shares in connection with stock option exercise | $ 1 | 1,523 | $ 1,524 | |||
Issuance of shares in connection with stock option exercise (in shares) | 972 | 972 | ||||
Issuance of shares in connection with restricted stock units vesting | $ 1 | $ 1 | ||||
Issuance of shares in connection with restricted stock units vesting (in shares) | 495 | |||||
Issuance of shares in connection with BOD Fees | $ 1 | 6 | 6 | |||
Issuance of shares in connection with ESPP | 221 | 221 | ||||
Issuance of shares in connection with ESPP (in shares) | 42 | |||||
Share-based compensation | 4,170 | 4,170 | ||||
Unrealized gain (loss) on deferred compensation trust assets | 24 | 24 | ||||
Ending balance at Apr. 01, 2023 | $ 59 | $ 303,185 | $ (7,625) | $ 1,150 | $ (179,700) | $ 117,069 |
Ending balance (in shares) at Apr. 01, 2023 | 56,203 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Operating activities | ||
Net loss | $ 1,051 | $ 2,103 |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
Depreciation and amortization expense | 3,919 | 2,957 |
Amortization of intangible assets | 11 | 28 |
Share-based compensation expense | 3,899 | 3,992 |
Stock awards issued for non-employee director service | 6 | 6 |
Stock awards related to officers and directors stock purchase plan from payroll deferral | 23 | |
Amortization of deferred financing costs | 16 | 4 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (3,362) | (1,445) |
Inventory | 23,662 | (19,087) |
Other current assets | (511) | (998) |
Other non-current assets | (55) | (503) |
Accounts payable and accrued expenses | 2,399 | 18,296 |
Other current liabilities | 1,450 | (136) |
Right-of-use obligation - operating leases - current | 181 | 125 |
Right-of-use obligation - operating leases - long-term | (117) | (1) |
Other non-current liabilities | 232 | (98) |
Net cash provided by (used in) operating activities | 32,781 | 5,266 |
Investing activities | ||
Additions to property and equipment | (2,745) | (3,760) |
Net cash used in investing activities | (2,745) | (3,760) |
Financing activities | ||
Borrowings from revolving loan payable | 76 | 5,032 |
Payments made on revolving loan payable | (76) | (32) |
Payments on finance leases | (1,242) | (844) |
Net proceeds from issuance of common stock | 221 | 431 |
Proceeds from exercise of stock options | 1,523 | 792 |
Net cash (used in) provided by financing activities | 502 | 5,379 |
Effect of exchange rate changes on cash | 6 | |
Net change in cash and cash equivalents | 30,538 | 6,891 |
Cash and cash equivalents, beginning of period | 18,767 | |
Cash and cash equivalents, end of period | 49,305 | 25,035 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Right-of-use finance asset acquired | 3,206 | |
Accrued asset purchases | 312 | 1,560 |
Share-based compensation expense capitalized in property and equipment | 271 | 314 |
Stock issued for services | 81 | |
Supplemental disclosure of cash flow information: | ||
Cash paid during the period for income taxes | (34) | 15 |
Cash paid during the period for interest | $ 381 | $ 306 |
Basis of Presentation and Descr
Basis of Presentation and Description of Company | 3 Months Ended |
Apr. 01, 2023 | |
Summary of Significant Accounting Policies and Nature of Operations | |
Basis of Presentation and Description of Company | Note 1 – Basis of Presentation and Description of Company CarParts.com, Inc. (including its subsidiaries) is a leading online provider of aftermarket auto parts and accessories. The Company sells its products primarily to individual consumers through its flagship website located at www.carparts.com www.carparts.com/investor The Company’s products consist of replacement parts serving the wear and tear and body repair market, hard parts to serve the maintenance and repair market, and performance parts and accessories. The replacement parts category is primarily comprised of body parts for the exterior of an automobile as well as certain other mechanical or electrical parts that are not related to the functioning of the engine or drivetrain. Our parts in this category typically replace original body parts that have been damaged as a result of general wear and tear or a collision. In addition, we sell an extensive line of mirror products, including parts from our own house brand called Kool-Vue ® ® ® The Company is a Delaware C corporation and is headquartered in Torrance, California. The Company has employees located in both the United States and the Philippines. Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to U.S. Securities and Exchange Commission (“SEC”) Form 10-Q and Article 10 of SEC Regulation S-X. In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, necessary to present fairly the consolidated financial position of the Company as of April 1, 2023 and the consolidated results of operations and cash flows for the thirteen weeks ended April 1, 2023 and April 2, 2022. The Company’s results for the interim periods are not necessarily indicative of the results that may be expected for any other interim period, or for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 8, 2023 and all our other periodic filings, including Current Reports on Form 8-K, filed with the SEC after the end of our 2022 fiscal year, and throughout the date of this report. Effective July 3, 2022, management reassessed our functional currency determination for our Philippines subsidiary in accordance with ASC 830, Foreign Currency Matters Based on our current operating plan, we believe that our existing cash, cash equivalents, investments, cash flows from operations and available debt financing will be sufficient to finance our operational cash needs through at least the next twelve months. |
Borrowings
Borrowings | 3 Months Ended |
Apr. 01, 2023 | |
Borrowings | |
Borrowings | Note 2 – Borrowings The Company maintains an asset-based revolving credit facility ("Credit Facility") that provides for, among other things, a revolving commitment, which is subject to a borrowing base derived from certain receivables, inventory, and property and equipment. The Credit Facility provides for the revolving commitment in an aggregated principal amount of $75,000 and allows for an uncommitted ability to increase the aggregate principal amount by an additional $75,000 to $150,000, subject to certain terms and conditions. The Credit Facility matures on June 17, 2027. As of April 1, 2023 and December 31, 2022, our outstanding revolving loan balance was $0. As of April 1, 2023 and December 31, 2022, the outstanding standby letters of credit balance was $620, and we had $0 of our trade letters of credit outstanding in accounts payable in our consolidated balance sheets. Loans drawn under the Credit Facility bear interest, at the Company’s option, at a per annum rate equal to either (a) Adjusted Secured Overnight Financing Rate (“SOFR”) plus an applicable margin of 1.50% to 2.00% per annum based on the Company's fixed charge coverage ratio, or (b) an “alternate prime base rate” subject to an increase from 0.00% to 0.50% per annum based on the Company’s fixed charge coverage ratio. As of April 1, 2023, the Company’s SOFR based interest rate was 6.90% and the Company’s prime based rate was 8.50%. A commitment fee, based upon undrawn availability under the Credit Facility bearing interest at a rate of either 0.20% or 0.25% per annum based on the amount of undrawn availability, is payable monthly. Under the terms of the credit agreement with JPMorgan Chase Bank, N.A. (the “Credit Agreement”), cash receipts are deposited into a lock-box, which are at the Company’s discretion unless the “cash dominion period” is in effect, during which cash receipts will be used to reduce amounts owing under the Credit Agreement. The cash dominion period is triggered in an event of default or if “excess availability,” as defined under the Credit Agreement, is less than $9,000 (12% of the aggregate revolving commitment) for three |
Stockholders' Equity and Share-
Stockholders' Equity and Share-Based Compensation | 3 Months Ended |
Apr. 01, 2023 | |
Stockholders' Equity and Share-Based Compensation | |
Stockholders' Equity and Share-Based Compensation | Note 3 – Stockholders’ Equity and Share-Based Compensation Options and Restricted Stock Units The Company had the following common stock option activity during the thirteen weeks ended April 1, 2023: ● Granted options to purchase 0 common shares. ● Exercise of 972 options to purchase common shares. ● Forfeiture of 1 option to purchase common shares. ● Expiration of 4 options to purchase common shares. The following table summarizes the Company’s restricted stock unit ("RSU") activity for the thirteen weeks ended April 1, 2023, and details regarding the awards outstanding and exercisable as of April 1, 2023 (in thousands): Weighted Weighted Average Average Grant Date Aggregate Shares Exercise Price Fair Value Intrinsic Value Vested and expected to vest as of December 31, 2022 3,132 $ — Awarded 1,455 $ — Vested (496) $ — Forfeited (52) $ — Awards outstanding, April 1, 2023 4,039 $ — $ 10.48 $ 21,569 Vested and expected to vest as of April 1, 2023 4,060 $ — $ 10.47 $ 21,682 During the thirteen weeks ended April 1, 2023, 227 RSUs that vested were time-based and 269 were performance-based. For the thirteen weeks ended April 1, 2023, we recorded compensation costs related to stock options and RSUs of $4,170. For the thirteen weeks ended April 2, 2022, we recorded compensation costs related to stock options and RSUs of $4,306, of which $81 related to common shares issued to consultants as part of their compensation for services provided during the period. As of April 1, 2023, there was unrecognized compensation expense related to stock options and RSUs of $30,197 that will be expensed through March 2027. |
Net Income Per Share
Net Income Per Share | 3 Months Ended |
Apr. 01, 2023 | |
Net Loss Per Share | |
Net Income Per Share | Note 4 – Net Income Per Share The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share data): Thirteen Weeks Ended April 1, 2023 April 2, 2022 Net income per share: Numerator: Net income allocable to common shares $ 1,051 $ 2,103 Denominator: Weighted-average common shares outstanding (basic) 55,047 53,251 Common equivalent shares from common stock options and restricted stock 2,990 3,921 Weighted-average common shares outstanding (diluted) 58,037 57,172 Basic net income per share $ 0.02 $ 0.04 Diluted net income per share $ 0.02 $ 0.04 Options and RSUs that were antidilutive and not included in the dilutive earnings per share calculation for the thirteen weeks ended April 1, 2023 and the thirteen weeks ended April 2, 2022 amounted to 1,456 and 3,011, respectively. |
Income Taxes
Income Taxes | 3 Months Ended |
Apr. 01, 2023 | |
Income Taxes | |
Income Taxes | Note 5 – Income Taxes The Company is subject to U.S. federal income tax as well as income tax of foreign and state tax jurisdictions. The tax years 2018-2022 remain open to examination by the major taxing jurisdictions to which the Company is subject, except the Internal Revenue Service for which the tax years 2019-2022 remain open. For the thirteen weeks ended April 1, 2023, the effective tax rate for the Company was 11.8% The effective tax rate differed from the U.S. federal statutory rate primarily due to state income taxes, share-based compensation that is either not deductible for tax purposes or for which the tax deductible amount is different than the financial reporting amount, and a change in the valuation allowance that offset the tax on the current period pre-tax income. For the thirteen weeks ended April 2, 2022, the effective tax rate for the Company was 2.4%. The effective tax rate differed from the U.S. federal statutory rate primarily due to state income taxes, share-based compensation that is either not deductible for tax purposes or for which the tax deductible amount is different than the financial reporting amount, and a change in the valuation allowance that offset the tax of the current period pre-tax income. The Company accounts for income taxes in accordance with ASC Topic 740 - Income Taxes (“ASC 740”). Under the provisions of ASC 740, management is required to evaluate whether a valuation allowance should be established against its deferred tax assets. We currently have a full valuation allowance against our deferred tax assets. As of each reporting date, the Company’s management considers new evidence, both positive and negative, that could impact management’s view with regard to future realization of deferred tax assets. For the thirteen weeks ended April 1, 2023, there was no material change from fiscal year ended December 31, 2022 in the amount of the Company's deferred tax assets that are not considered to be more likely than not to be realized in future years. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Apr. 01, 2023 | |
Commitments and Contingencies. | |
Commitments and Contingencies | Note 6 – Commitments and Contingencies Legal Matters Asbestos . Ordinary course litigation. |
Product Information
Product Information | 3 Months Ended |
Apr. 01, 2023 | |
Product Information | |
Product Information | Note 7 – Product Information As described in Note 1 above, the Company’s products consist of replacement parts serving the wear and tear and body repair market, hard parts to serve the maintenance and repair market, and performance parts and accessories. The following table summarizes the approximate distribution of the Company’s revenue by product type. Thirteen Weeks Ended April 1, 2023 April 2, 2022 House Brands Replacement Parts 68 % 65 % Hard Parts 19 % 22 % Performance 1 % — % Branded Replacement Parts 1 % 1 % Hard Parts 6 % 7 % Performance 5 % 5 % Total 100 % 100 % |
Basis of Presentation and Des_2
Basis of Presentation and Description of Company (Policies) | 3 Months Ended |
Apr. 01, 2023 | |
Summary of Significant Accounting Policies and Nature of Operations | |
Basis of Presentation | Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to U.S. Securities and Exchange Commission (“SEC”) Form 10-Q and Article 10 of SEC Regulation S-X. In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, necessary to present fairly the consolidated financial position of the Company as of April 1, 2023 and the consolidated results of operations and cash flows for the thirteen weeks ended April 1, 2023 and April 2, 2022. The Company’s results for the interim periods are not necessarily indicative of the results that may be expected for any other interim period, or for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 8, 2023 and all our other periodic filings, including Current Reports on Form 8-K, filed with the SEC after the end of our 2022 fiscal year, and throughout the date of this report. Effective July 3, 2022, management reassessed our functional currency determination for our Philippines subsidiary in accordance with ASC 830, Foreign Currency Matters Based on our current operating plan, we believe that our existing cash, cash equivalents, investments, cash flows from operations and available debt financing will be sufficient to finance our operational cash needs through at least the next twelve months. |
Stockholders' Equity and Shar_2
Stockholders' Equity and Share-Based Compensation (Tables) | 3 Months Ended |
Apr. 01, 2023 | |
Stockholders' Equity and Share-Based Compensation | |
Summary of Restricted Stock Unit Activity | The following table summarizes the Company’s restricted stock unit ("RSU") activity for the thirteen weeks ended April 1, 2023, and details regarding the awards outstanding and exercisable as of April 1, 2023 (in thousands): Weighted Weighted Average Average Grant Date Aggregate Shares Exercise Price Fair Value Intrinsic Value Vested and expected to vest as of December 31, 2022 3,132 $ — Awarded 1,455 $ — Vested (496) $ — Forfeited (52) $ — Awards outstanding, April 1, 2023 4,039 $ — $ 10.48 $ 21,569 Vested and expected to vest as of April 1, 2023 4,060 $ — $ 10.47 $ 21,682 |
Net Income Per Share (Tables)
Net Income Per Share (Tables) | 3 Months Ended |
Apr. 01, 2023 | |
Net Loss Per Share | |
Computation of Basic and Diluted Net Income (Loss) Per Share | The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share data): Thirteen Weeks Ended April 1, 2023 April 2, 2022 Net income per share: Numerator: Net income allocable to common shares $ 1,051 $ 2,103 Denominator: Weighted-average common shares outstanding (basic) 55,047 53,251 Common equivalent shares from common stock options and restricted stock 2,990 3,921 Weighted-average common shares outstanding (diluted) 58,037 57,172 Basic net income per share $ 0.02 $ 0.04 Diluted net income per share $ 0.02 $ 0.04 |
Product Information (Tables)
Product Information (Tables) | 3 Months Ended |
Apr. 01, 2023 | |
Product Information | |
Summary of Revenue by Product Type | Thirteen Weeks Ended April 1, 2023 April 2, 2022 House Brands Replacement Parts 68 % 65 % Hard Parts 19 % 22 % Performance 1 % — % Branded Replacement Parts 1 % 1 % Hard Parts 6 % 7 % Performance 5 % 5 % Total 100 % 100 % |
Borrowings (Details)
Borrowings (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Jun. 17, 2022 | |
JP Morgan | Revolving Credit Facility | ||
Borrowings | ||
Current borrowing capacity | $ 75,000 | |
Maximum borrowing capacity | 150,000 | |
Increased aggregate borrowing capacity | $ 75,000 | |
Revolving loan payable | $ 0 | |
Credit facility trigger amount | $ 9,000 | |
Consecutive business days below minimum excess availability | 3 days | |
Number of consecutive days excess availability is above required amount | 45 days | |
Minimum availability required under availability block | $ 7,500 | |
Minimum fixed charge ratio if less than minimum excess availability | 1 | |
Event of default amount | $ 0 | |
JP Morgan | Revolving Credit Facility | Minimum | ||
Borrowings | ||
Unused credit commitment fee (percent) | 0.25% | |
JP Morgan | Revolving Credit Facility | Maximum | ||
Borrowings | ||
Unused credit commitment fee (percent) | 0.20% | |
JP Morgan | Letter of Credit | ||
Borrowings | ||
Maximum borrowing capacity | $ 620 | |
Outstanding letters of credit amount | $ 0 | |
Adjusted Secured Overnight Financing Rate (SOFR) | Revolving Credit Facility | Minimum | ||
Borrowings | ||
Applicable margin on the company's fixed charge coverage ratio (percent) | 1.50% | |
Adjusted Secured Overnight Financing Rate (SOFR) | Revolving Credit Facility | Maximum | ||
Borrowings | ||
Applicable margin on the company's fixed charge coverage ratio (percent) | 2% | |
Adjusted Secured Overnight Financing Rate (SOFR) | JP Morgan | Revolving Credit Facility | ||
Borrowings | ||
Interest rate (percent) | 6.90% | |
Base Rate | JP Morgan | Revolving Credit Facility | ||
Borrowings | ||
Interest rate (percent) | 8.50% | |
Prime rate | Revolving Credit Facility | Minimum | ||
Borrowings | ||
Applicable margin on the company's fixed charge coverage ratio (percent) | 0% | |
Prime rate | Revolving Credit Facility | Maximum | ||
Borrowings | ||
Applicable margin on the company's fixed charge coverage ratio (percent) | 0.50% |
Borrowings - Additional Informa
Borrowings - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Jun. 17, 2022 | |
JP Morgan | Revolving Credit Facility | ||
Borrowings | ||
Current borrowing capacity | $ 75,000 | |
Maximum borrowing capacity | 150,000 | |
Increased aggregate borrowing capacity | $ 75,000 | |
Revolving loan payable | $ 0 | |
Credit facility trigger amount | $ 9,000 | |
Credit facility trigger amount as a percent of aggregate revolving commitment (in percent) | 12% | |
Consecutive business days below minimum excess availability | 3 days | |
Number of consecutive days excess availability is above required amount | 45 days | |
Event of default amount | $ 0 | |
Minimum availability required under availability block | $ 7,500 | |
Minimum availability required under availability block as a percentage of aggregate revolving commitment (in percent) | 10% | |
Minimum fixed charge ratio if less than minimum excess availability | 1 | |
JP Morgan | Revolving Credit Facility | Maximum | ||
Borrowings | ||
Unused credit commitment fee (percent) | 0.20% | |
JP Morgan | Revolving Credit Facility | Minimum | ||
Borrowings | ||
Unused credit commitment fee (percent) | 0.25% | |
JP Morgan | Letter of Credit | ||
Borrowings | ||
Maximum borrowing capacity | $ 620 | |
Outstanding letters of credit amount | $ 0 | |
Base Rate | JP Morgan | Revolving Credit Facility | ||
Borrowings | ||
Interest rate (percent) | 8.50% | |
Prime rate | Revolving Credit Facility | Maximum | ||
Borrowings | ||
Applicable margin on the company's fixed charge coverage ratio (percent) | 0.50% | |
Prime rate | Revolving Credit Facility | Minimum | ||
Borrowings | ||
Applicable margin on the company's fixed charge coverage ratio (percent) | 0% | |
Adjusted Secured Overnight Financing Rate (SOFR) | Revolving Credit Facility | Maximum | ||
Borrowings | ||
Applicable margin on the company's fixed charge coverage ratio (percent) | 2% | |
Adjusted Secured Overnight Financing Rate (SOFR) | Revolving Credit Facility | Minimum | ||
Borrowings | ||
Applicable margin on the company's fixed charge coverage ratio (percent) | 1.50% | |
Adjusted Secured Overnight Financing Rate (SOFR) | JP Morgan | Revolving Credit Facility | ||
Borrowings | ||
Interest rate (percent) | 6.90% |
Stockholders' Equity and Shar_3
Stockholders' Equity and Share-Based Compensation - Summary of Stock Option Activity (Details) shares in Thousands | 3 Months Ended |
Apr. 01, 2023 shares | |
Shares | |
Granted (in shares) | 0 |
Exercised (in shares) | (972) |
Cancelled: | |
Forfeited (in shares) | (1) |
Expired (in shares) | (4) |
Stockholders' Equity and Shar_4
Stockholders' Equity and Share-Based Compensation - Public Equity Offering (Details) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Stockholders' Equity and Share-Based Compensation | ||
Net proceeds from issuance of common stock | $ 221 | $ 431 |
Time Based RSU | ||
Stockholders' Equity and Share-Based Compensation | ||
Vested (in shares) | 227 | |
Performance based RSU | ||
Stockholders' Equity and Share-Based Compensation | ||
Vested (in shares) | 269 | |
Restricted stock units | ||
Stockholders' Equity and Share-Based Compensation | ||
Vested (in shares) | 496 |
Stockholders' Equity and Shar_5
Stockholders' Equity and Share-Based Compensation - Share-Based Compensation Plan Information (Details) shares in Thousands | 3 Months Ended |
Apr. 01, 2023 shares | |
Stockholders' Equity and Share-Based Compensation | |
Number of shares granted (in shares) | 0 |
Stockholders' Equity and Shar_6
Stockholders' Equity and Share-Based Compensation - Restricted Stock Units (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Stock options and Restricted stock units | ||
Stockholders' Equity and Share-Based Compensation | ||
Compensation costs | $ 4,170 | $ 4,306 |
Unrecognized compensation expense | $ 30,197 | |
Stock options and Restricted stock units | Consultant | ||
Stockholders' Equity and Share-Based Compensation | ||
Compensation costs | $ 81 | |
Restricted stock units | ||
Stockholders' Equity and Share-Based Compensation | ||
Awarded (in shares) | 1,455 | |
Closing price of grant (in dollars per share) | $ 10.48 | |
Vested (in shares) | 496 | |
Awards forfeited (in shares) | 52 | |
Time Based RSU | ||
Stockholders' Equity and Share-Based Compensation | ||
Vested (in shares) | 227 | |
Performance based RSU | ||
Stockholders' Equity and Share-Based Compensation | ||
Vested (in shares) | 269 |
Stockholders' Equity and Shar_7
Stockholders' Equity and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended |
Apr. 01, 2023 USD ($) $ / shares shares | |
Restricted stock units | |
Shares | |
Vested and expected to vest as of January 1, 2022 (in shares) | 3,132 |
Awarded (in shares) | 1,455 |
Vested (in shares) | (496) |
Forfeited (in shares) | (52) |
Awards outstanding, July 2, 2022 (in shares) | 4,039 |
Vested and expected to vest as of July 2, 2022 (in shares) | 4,060 |
Weighted Average Exercise Price | |
Awards outstanding, weighted average exercise price, ending balance (in usd per share) | $ / shares | $ 10.48 |
Vested and expected to vest, weighted average exercise price, ending balance (in usd per share) | $ / shares | 10.47 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] | |
Awards outstanding, Aggregate Intrinsic Value | $ | $ 21,569 |
Vested and expected to vest, Aggregate Intrinsic Value | $ | $ 21,682 |
Time Based RSU | |
Shares | |
Vested (in shares) | (227) |
Performance based RSU | |
Shares | |
Vested (in shares) | (269) |
Stockholders' Equity and Shar_8
Stockholders' Equity and Share-Based Compensation - Share-Based Compensation Expense (Details) - Stock options and Restricted stock units - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Stockholders' Equity and Share-Based Compensation | ||
Unrecognized compensation expense | $ 30,197 | |
Compensation costs | $ 4,170 | $ 4,306 |
Net Loss Per Share (Details)
Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Net Loss Per Share | ||
Net loss allocable to common shares | $ 1,051 | $ 2,103 |
Common equivalent shares from common stock options and restricted stock | 2,990 | 3,921 |
Weighted-average common shares outstanding (basic) | 55,047 | 53,251 |
Weighted-average common shares outstanding (diluted) | 58,037 | 57,172 |
Basic net loss per share | $ 0.02 | $ 0.04 |
Diluted net loss per share | $ 0.02 | $ 0.04 |
Net Income (Loss) Per Share - A
Net Income (Loss) Per Share - Anti-Dilutive Securities (Details) - shares shares in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Net Loss Per Share | ||
Anti-dilutive securities excluded from calculation of diluted earnings per share (in shares) | 1,456 | 3,011 |
Income Taxes - Components of Lo
Income Taxes - Components of Loss From Operations (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Income Taxes | ||
Loss before income taxes | $ 1,192 | $ 2,155 |
Income Taxes - Summary of Incom
Income Taxes - Summary of Income Tax Provision (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Income Taxes | ||
Income tax provision | $ 141 | $ 52 |
Income Taxes - Summary of Diffe
Income Taxes - Summary of Differences Between Income Tax Provision and Applied Federal Statutory Rate (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Income Taxes | ||
Income tax provision | $ 141 | $ 52 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Income Taxes | ||
Effective tax rate | 11.80% | 2.40% |
Commitments and Contingencies -
Commitments and Contingencies - Quantitative Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Commitments and Contingencies. | ||
Financing cash outflow from financing leases | $ 1,242 | $ 844 |
Commitments and Contingencies_2
Commitments and Contingencies - Quantitative Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Cash paid for amounts included in the measurement of lease liabilities: | ||
Financing cash outflow from financing leases | $ 1,242 | $ 844 |
Product Information - Summary o
Product Information - Summary of Segment Percentages (Details) - Sales Revenue, Product Line - Product Concentration Risk | 3 Months Ended | |
Apr. 01, 2023 | Apr. 02, 2022 | |
Product Information | ||
Concentration risk percentage | 100% | 100% |
House Brands, Replacement Parts | ||
Product Information | ||
Concentration risk percentage | 68% | 65% |
House Brands, Hard Parts | ||
Product Information | ||
Concentration risk percentage | 19% | 22% |
House Brands, Performance | ||
Product Information | ||
Concentration risk percentage | 1% | |
Branded, Replacement Parts | ||
Product Information | ||
Concentration risk percentage | 1% | 1% |
Branded, Hard Parts | ||
Product Information | ||
Concentration risk percentage | 6% | 7% |
Branded, Performance | ||
Product Information | ||
Concentration risk percentage | 5% | 5% |